全文获取类型
收费全文 | 637篇 |
免费 | 54篇 |
国内免费 | 7篇 |
专业分类
耳鼻咽喉 | 1篇 |
儿科学 | 32篇 |
妇产科学 | 4篇 |
基础医学 | 48篇 |
口腔科学 | 32篇 |
临床医学 | 60篇 |
内科学 | 147篇 |
皮肤病学 | 20篇 |
神经病学 | 15篇 |
特种医学 | 138篇 |
外科学 | 42篇 |
综合类 | 76篇 |
预防医学 | 17篇 |
药学 | 37篇 |
1篇 | |
肿瘤学 | 28篇 |
出版年
2022年 | 3篇 |
2021年 | 3篇 |
2020年 | 1篇 |
2019年 | 4篇 |
2018年 | 11篇 |
2017年 | 7篇 |
2016年 | 10篇 |
2015年 | 13篇 |
2014年 | 17篇 |
2013年 | 15篇 |
2012年 | 12篇 |
2011年 | 8篇 |
2010年 | 20篇 |
2009年 | 28篇 |
2008年 | 13篇 |
2007年 | 14篇 |
2006年 | 33篇 |
2005年 | 8篇 |
2004年 | 11篇 |
2003年 | 17篇 |
2002年 | 8篇 |
2001年 | 9篇 |
2000年 | 6篇 |
1999年 | 7篇 |
1998年 | 30篇 |
1997年 | 50篇 |
1996年 | 45篇 |
1995年 | 33篇 |
1994年 | 34篇 |
1993年 | 36篇 |
1992年 | 19篇 |
1991年 | 9篇 |
1990年 | 12篇 |
1989年 | 13篇 |
1988年 | 17篇 |
1987年 | 9篇 |
1986年 | 6篇 |
1985年 | 8篇 |
1984年 | 9篇 |
1983年 | 11篇 |
1982年 | 16篇 |
1981年 | 14篇 |
1980年 | 8篇 |
1979年 | 5篇 |
1978年 | 4篇 |
1977年 | 6篇 |
1976年 | 15篇 |
1975年 | 9篇 |
1973年 | 1篇 |
1971年 | 1篇 |
排序方式: 共有698条查询结果,搜索用时 15 毫秒
41.
RS de Vreeze D de Jong IH Tielen HJ Ruijter PM Nederlof RL Haas F van Coevorden 《Modern pathology》2009,22(2):223-231
Almost all primary retroperitoneal liposarcomas can be classified as well-/dedifferentiated liposarcoma. Rarely, however, primary retroperitoneal liposarcoma is classified as myxoid/round cell liposarcoma, based on the presence of myxoid areas and vascular crow's feet pattern, which has resulted in a debate on the classification of liposarcoma in the retroperitoneum. Genetically, myxoid/round cell liposarcoma and well-/dedifferentiated liposarcoma are different diseases. Myxoid/round cell liposarcoma is characterized by a translocation causing FUS-CHOP or EWSR1-CHOP fusion, whereas well-/dedifferentiated liposarcoma is characterized by an amplification of the 12q13-15 region, including MDM2 and CDK4 genes. As myxoid/round cell liposarcoma is highly radio- and chemosensitive, differentiation between subtypes is important to optimize treatment. We studied whether primary retroperitoneal liposarcomas diagnosed as myxoid/round cell liposarcoma represent molecularly true myxoid/round cell liposarcoma or are histopathological mimics and represent well-/dedifferentiated liposarcoma. Primary retroperitoneal myxoid/round cell liposarcoma (n=16) were compared to primary extremity myxoid/round cell liposarcoma (n=20). Histopathological and immunohistochemical features were studied. Amplification status of the 12q13-15 region was studied using a multiplex ligation-dependent probe amplification analysis, and FUS-CHOP or EWS-CHOP translocations were studied using RT-PCR. In primary retroperitoneal myxoid/round cell liposarcoma, MDM2 and CDK4 staining was both positive in 12 of 15 cases. In primary extremity myxoid/round cell liposarcoma, MDM2 was negative in 18/20 and CDK4 was negative in all cases. Multiplex ligation-dependent probe amplification showed the amplification of 12q13-15 region in 16/16 primary retroperitoneal myxoid/round cell liposarcomas and in 1/20 primary extremity myxoid/round cell liposarcomas. Translocation was present in all (18/18) primary extremity myxoid/round cell liposarcomas, but absent in all primary retroperitoneal myxoid/round cell liposarcomas. On the basis of immunohistochemical and molecular characteristics, apparent primary retroperitoneal myxoid/round cell liposarcoma can be recognized as well-/dedifferentiated liposarcoma with morphological features mimicking myxoid/round cell liposarcoma. In these cases, treatment should probably be specifically designed as for well-/dedifferentiated liposarcoma. Moreover, finding of myxoid/round cell liposarcoma translocations in a retroperitoneal localization is highly suggestive of metastasis and should prompt search for a primary localization outside the retroperitoneum. 相似文献
42.
43.
Anti-thrombotic therapy for non-rheumatic atrial fibrillation 总被引:1,自引:0,他引:1
Recent randomized trials of antithrombotic therapy in non-rheumatic atrial
fibrillation have helped to clarify the benefits of warfarin and aspirin.
Low-risk patients (normotensives aged <60 with normal left
ventricular function) have a small risk of thromboembolic events and are
unlikely to benefit significantly from anticoagulants, but may benefit from
aspirin with little increase in risk of bleeding. High-risk patients
(>75 years, impaired left ventricular function, previous
thromboembolism and/or associated conditions such as hypertension and
diabetes mellitus) have an increased risk of thromboembolism, and benefit
from long-term anticoagulant therapy to a greater degree than with aspirin,
although at a risk of increased bleeding complications.
相似文献
44.
Serologic test for syphilis as a surrogate marker for human immunodeficiency virus infection among United States blood donors 总被引:2,自引:0,他引:2
GA Herrera ; EM Lackritz ; RS Janssen ; VP Raimondi ; RY Dodd ; J Aberle-Grasse ; LR Petersen 《Transfusion》1997,37(8):836-840
BACKGROUND: This study evaluated the usefulness of the serologic test for syphilis (STS) in preventing the transmission of human immunodeficiency virus (HIV), hepatitis B and C viruses, and human T- lymphotropic virus via the transfusion of seronegative, infectious window-period blood. STUDY DESIGN AND METHODS: Demographic and laboratory information on blood donations made between January 1992 and June 1994 in 18 American Red Cross regions was analyzed. It was assumed that the same proportion of HIV-positive and HIV-infectious window- period donations reacted on STS and were negative on other screening tests (hepatitis B and C viruses and human T-lymphotropic virus). This proportion multiplied by the estimated number of HIV-infectious window- period donations is the number of post-screening HIV-infectious donations removed by STS. RESULTS: Of 4,468,570 donations, 12,145 (0.27%) were STS positive and 377 (0.008%) were HIV positive. Among donations that were negative on other screening tests, STS-reactive donations were 12 times more likely to be HIV positive (odds ratio = 11.9; 95% CI = 5,26). However, of an estimated 13 infectious window- period donations, 0.2 would have been removed because of a reactive STS, at a cost of over $16 million. CONCLUSION: STS is a poor marker and a costly strategy for preventing post-screening HIV infections and other blood-borne diseases. 相似文献
45.
The pharmacology of a new pasteurized factor VIII (FVIII) concentrate derived from human blood plasma was studied in 23 adults with hemophilia A. In Part 1 of the study involving six nonbleeding subjects, the mean increase in FVIII activity was 1.43 +/- 0.34 U per ml 10 minutes after an intravenous dose of 50 U per kg. The intravascular survival kinetics in these six patients showed a biphasic decay curve with an initial mean half-life of 5.1 +/- 1.2 hours probably representing early redistribution, and a late half-life of 13.3 +/- 4.9 hours. In Part 2 of the study, the activity at 10 minutes was measured in another 17 patients, as well as in one patient already studied in Part 1. The mean increase in activity with the 24 observations was 1.13 +/- 0.37 U per ml with a mean FVIII dosage of 51.0 +/- 2.6 U per kg of body weight. Only one patient had an allergic reaction, which did not recur when the patient was given a second lot. 相似文献
46.
In vitro and in vivo activity of murine lymphokine-activated killer cells after cryopreservation 总被引:1,自引:0,他引:1
The in vitro and in vivo effects of cryopreservation on the cytotoxic activity of murine lymphokine-activated killer (LAK) cells were studied. LAK cells were generated by incubation of spleen lymphocytes of BALB/c mice for 3 days with recombinant interleukin-2 (rIL-2) and subsequent cryopreservation. Cytotoxicity was determined in a 51Cr release assay. After thawing, cytotoxic activity was reduced (40.4% 51Cr release at an effector:target cell ratio of 40:1 as compared to 68.5% 51Cr release before freezing) and could be restored to precryopreserved levels by reincubation with rIL-2 for 2 days after thawing (78.8% 51Cr release). These cells were then tested in BALB/c mice injected with RAW 112 cells, a pre-B-cell lymphoma line. The results demonstrate that the survival rate of mice injected with cryopreserved and restimulated LAK cells (50% survival greater than 180 days after injection) did not differ significantly from that of mice injected with fresh unfrozen LAK cells (60% survival greater than 120 days, 50% survival greater than 180 days). Cryopreserved LAK cells have potential use in adoptive immunotherapy. 相似文献
47.
48.
49.
50.